Chronic Kidney Disease - Pipeline Review, H1 2017

  • ID: 4239813
  • Drug Pipelines
  • 195 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • BLR Bio LLC
  • CTI BioPharma Corp
  • Lupin Ltd
  • Regulus Therapeutics Inc
  • Tricida Inc
  • MORE
Chronic Kidney Disease - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • BLR Bio LLC
  • CTI BioPharma Corp
  • Lupin Ltd
  • Regulus Therapeutics Inc
  • Tricida Inc
  • MORE
Introduction

Chronic Kidney Disease (Chronic Renal Failure) - Overview

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development

Angion Biomedica Corp

apceth Biopharma GmbH

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BLR Bio LLC

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Cellmid Ltd

Chugai Pharmaceutical Co Ltd

Complexa Inc

Corvidia Corp

CTI BioPharma Corp

Evotec AG

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

GNI Group Ltd

Lupin Ltd

Navya Biologicals Pvt Ltd

Nippon Zoki Pharmaceutical Co Ltd

Novartis AG

Otsuka Holdings Co Ltd

Prismic Pharmaceuticals Inc

Prolong Pharmaceuticals LLC

ProMetic Life Sciences Inc

Reata Pharmaceuticals Inc

Regulus Therapeutics Inc

Relypsa Inc

Resverlogix Corp

Spotlight Innovation Inc

Taisho Pharmaceutical Co Ltd

Toray Industries Inc

Tricida Inc

Unity Biotechnology Inc

Vascular BioSciences

VESSL Therapeutics Ltd

Vicore Pharma AB

Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles

(palmidrol + silibinin) - Drug Profile

ambrisentan - Drug Profile

ANG-3070 - Drug Profile

ANG-3281 - Drug Profile

ANG-3586 - Drug Profile

Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile

apabetalone - Drug Profile

AS-2444697 - Drug Profile

bardoxolone methyl - Drug Profile

BI-655088 - Drug Profile

BKE-001 - Drug Profile

BLR-400 - Drug Profile

C-21 - Drug Profile

CAB-101 - Drug Profile

calcium succinate - Drug Profile

CAR Peptide - Drug Profile

cardiotoxin - Drug Profile

Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile

COR-001 - Drug Profile

CXA-10 - Drug Profile

dapagliflozin propanediol - Drug Profile

Drug for Kidney Diseases - Drug Profile

Drug to Activate sGC for Chronic Kidney Disease - Drug Profile

EOS-789 - Drug Profile

F-351 - Drug Profile

finerenone - Drug Profile

FM-1302 - Drug Profile

KBP-5074 - Drug Profile

LHW-090 - Drug Profile

MultiGeneGraft - Drug Profile

NAV-003 - Drug Profile

NZ-419 - Drug Profile

obinutuzumab - Drug Profile

pacritinib - Drug Profile

patiromer sorbitex calcium - Drug Profile

PBI-4050 - Drug Profile

Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile

Sanguinate - Drug Profile

Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile

Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease - Drug Profile

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile

Small Molecules for Chronic Kidney Disease - Drug Profile

Small Molecules for Chronic Kidney Disease - Drug Profile

SP-20103 - Drug Profile

SPR-494 - Drug Profile

Stem Cell Therapy for Chronic Kidney Disease - Drug Profile

Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile

Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile

tesidolumab - Drug Profile

tolvaptan - Drug Profile

torsemide ER - Drug Profile

TRC-101 - Drug Profile

TS-143 - Drug Profile

verinurad - Drug Profile

Vida-5 - Drug Profile

VS-105 - Drug Profile

Wnt-001 - Drug Profile

YS-1402 - Drug Profile

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products

Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BLR Bio LLC, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chugai Pharmaceutical Co Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Corp, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Regulus Therapeutics Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Relypsa Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Spotlight Innovation Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Tricida Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2017 (Contd..1), H1

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1

List of Figures:

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Angion Biomedica Corp
  • apceth Biopharma GmbH
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • BLR Bio LLC
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • Cellmid Ltd
  • Chugai Pharmaceutical Co Ltd
  • Complexa Inc
  • Corvidia Corp
  • CTI BioPharma Corp
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GNI Group Ltd
  • Lupin Ltd
  • Navya Biologicals Pvt Ltd
  • Nippon Zoki Pharmaceutical Co Ltd
  • Novartis AG
  • Otsuka Holdings Co Ltd
  • Prismic Pharmaceuticals Inc
  • Prolong Pharmaceuticals LLC
  • ProMetic Life Sciences Inc
  • Reata Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • Relypsa Inc
  • Resverlogix Corp
  • Spotlight Innovation Inc
  • Taisho Pharmaceutical Co Ltd
  • Toray Industries Inc
  • Tricida Inc
  • Unity Biotechnology Inc
  • Vascular BioSciences
  • VESSL Therapeutics Ltd
  • Vicore Pharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll